Comparison of Clinical Efficacy between Abiraterone, Enzalutamide and Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer

Tomaš I, Sablić M, Drežnjak-Madunić M, Šambić-Penc M and Matić M

Department of Nuclear Medicine and Oncology, Josip Juraj Strossmayer University of Osijek, Croatia
Department of Anatomy and Neuroscience, Josip Juraj Strossmayer University of Osijek, Croatia
Department of Oncology, Josip Juraj Strossmayer University of Osijek, Croatia

^*Correspondance to: Marko Sablić 

 PDF  Full Text Research Article | Open Access

Abstract:

Comparison of clinical efficacy between abiraterone, enzalutamide and docetaxel in patients with metastatic castrate-resistant prostate cancer in the Clinical Hospital Center Osijek.
Objective:The goal of this study was to determine if there is a significant difference in the progression-free survival time between patients with castrate-resistant metastatic prostate cancer treated with abiraterone compared with those on enzalutamide.
Study Design: Historical prospective study.
Materials and Methods: This study was conducted on patients treated at the Institute of Oncology of Clinical Hospital Center Osijek from January 2015 until May 2021. Inclusion criteria were the confirmed diagnosis of metastatic castrate resistant prostate cancer and treatment with either medication.
Results: The study included 83 patients of which 29 (35%) had docetaxel as the first line treatment, 28 (34%) had enzalutamide and 26 (31%) abiraterone. Median age of patients was 75 years and the PSA at the time of diagnosis was on average 44 ng/mL. Gleason score ≤ 7 was present in 44 (53%) and a score ≥ 8 in 35 (42%) of patients. Bone metastases were present in 73 (87%) patients, visceral metastasis in 19 (23%). There were 60 (72%) patients that had undergone surgery of which 43 (52%) had an orchidectomy and 20 (24%) a prostatectomy. Curative radiation therapy was conducted in 45 (51%) patients with the median dose being 66 Gy. Kaplan-Meier survival analysis showed no significant difference in progression-free survival between enzalutamide and abiraterone as first or second line treatment (Log Rank, P=0.77). Median time for overall survival was 15 months (8-25) with no difference between studied groups (P=0.06).
Conclusion: There is no significant difference between progression-free survival time between abiraterone and enzalutamide as a first line treatment for metastatic castrate resistant prostate cancer.

Keywords:

Prostate cancer; Abiraterone; MDV3100; Progression free survival

Cite the Article:

Tomaš I, Sablić M, Drežnjak-Madunić M, Šambić-Penc M, Matić M. Comparison of Clinical Efficacy between Abiraterone, Enzalutamide and Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer. Clin Oncol. 2022;7:1966..